Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Credo Technology thrives on AI infrastructure demand and Nvidia's success but faces valuation and risk concerns. Read what to ...

The U.S. government is pulling its funding for drugmaker Moderna to continue testing an mRNA vaccine intended to protect people from the bird flu.

More than $14 billion in clean energy investments in the U.S. have been canceled or delayed this year, according to an ...

The mental health of ATCOs is gaining increasing awareness. What initiatives are underway to support them and ensure safety ...

PDD Holdings' long-term value hinges more on macro stability than near-term execution. Learn more about PDD stock and my ...